Khiron Life Sciences Corp. has successfully delivered EU-GMP medical cannabis product to Germany. In collaboration with Nimbus Health, a leading medical cannabis distributor in Germany, Khiron is now positioned for imminent first sales in Germany. Khiron products are currently in inventory in the Nimbus warehouse, ready to be prescribed to patients and distributed through a vast network of 300 pharmacies across Germany. This major milestone represents a new revenue stream for the company and positions Khiron's European team to execute on its German medical strategy. Leveraging its partner's large distribution network and Khiron's ongoing investments in physician education, the Company has secured immediate access to the German market. Khiron 1/14 will focus on indications such as anxiety, substance use disorder, and migraines, addressing patient needs and improving access to medical cannabis. Through its EU-GMP certified supply chain partners in Europe, Khiron continues to expand its offering of world-class medical cannabis products, targeting the introduction of cannabis-based medicinal products based on those already distributed by the company in Colombia and Peru. With Khiron's proof of concept now validated in Colombia, the Company plans to leverage its clinical data and IP, educational platforms, and technology and systems to expand into new markets.